Jon Knight Email & Phone Number

Kamada Ltd. is a global specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities.

TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues.

Laval, Quebec

Prometic is a biopharmaceutical corporation with two drug discovery platforms focusing on unmet medical needs in the field of fibrosis and orphan diseases. We are committed to providing patients throughout the world with hope of a healthier future and are doing this by:• advancing our new discoveries within the lifecycle of healing through the clinical trial stages and regulatory approval process• targeting specific unmet medical needs using our proprietary small molecule and plasma-derived drug candidates• building a deep and rich R&D pipeline, enabled through world-class scienceWe are headquartered in Laval, Quebec (Canada), and have R&D facilities in Canada, the United States (“USA”) and United Kingdom (“UK”), manufacturing facilities in Canada and the Isle of Man and corporate and business development activities in Canada, the USA, Europe and Asia. Prometic is now focused on completing its transition from a pure R&D company into a commercially successful pharmaceutical company specialized in rare and orphan diseases with the foundations to enable significant growth over the coming years.Small Molecule TherapeuticsOur lead drug candidate program is PBI-4050, an orally active lead drug candidate with excellent safety and efficacy profiles demonstrated in a large number of animal models of fibrosis affecting different organs, including the lung, liver, heart, kidney, and pancreas. Plasma-Derived protein TherapeuticsThe second drug discovery and development platform (plasma-derived therapeutics) leverages Prometic’s experience in bioseparation technologies used to isolate and purify biopharmaceuticals from human plasma. The primary goal with respect to this second platform is to address unmet medical needs with therapeutic proteins not currently commercially available. We are also leveraging this platform’s higher recovery yield potential to advance established plasma-derived therapeutics such as Intravenous Immunoglobulin (IVIG).

Deloitte Advisory helps clients manage strategic, financial, operational, technological, and regulatory risk to enhance enterprise value, while our experience in mergers and acquisitions, fraud, litigation, and reorganizations helps clients emerge stronger and more resilient.CIS by Deloitte specializes in integrated compliance and commercial services for the life sciences and health care industry.Services are focused on risk mitigation and operational performance.

Cardinal Health, Inc. (NYSE: CAH), a global health services and products company, brings scaled solutions that help our customers thrive in a changing world. Cardinal Health improves the cost-effectiveness of healthcare through solutions that improve the efficiency of the supply chain; optimize the process and performance of healthcare; provide clinically proven, daily use medical products and pharmaceuticals; and connect patients, providers, payers, pharmacists and manufacturers for seamless care coordination and better patient management. Backed by nearly 100 years of experience, Cardinal Health ranks among the top 50 on the Fortune 500 and among the Fortune Global 100.

Cangene is one of Canada's largest biotechnology companies. It was founded in 1984 and is headquartered in Winnipeg, Manitoba. Cangene has been listed on the Toronto Stock Exchange since 1991 under the symbol CNJ. Cangene carries out research and development in Mississauga, Ontario and Winnipeg. It uses patented manufacturing processes to produce plasma-derived and recombinant therapeutic proteins in addition to offering contract R&D and manufacturing services to the biopharmaceutical industry.

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. We are poised to capture large commercial opportunities in our core business areas: Gram-positive bacterial infections, hepatitis, kidney disease (nephrology), and nicotine addiction. We have four products on the market today: WinRho SDF [Anti-D Immune Globulin (Human)], PhosLo® (calcium acetate), Nabi-HB® [Hepatitis B Immune Globulin (Human)], and Aloprim™ [Allopurinol sodium (for injection)] and a number of products in various stages of clinical and pre-clinical development. The company also filed Marketing Authorization Applications (MAA) in Europe to market Nabi-HB® Intravenous [Hepatitis B Immune Globulin (Human) Intravenous] under the trade name HEBIG™ for the prevention of hepatitis B disease in HBV-positive liver transplant patients; and for PhosLo, which is already marketed in the United States. The company's products in development include NicVAX, a vaccine to treat nicotine addiction, and Civacir, an antibody for preventing hepatitis C virus re-infection in liver transplant patients.